



Depression and Anxiety May Accelerate Burden in Care Partners of Patients with Parkinson's Disease: Findings from a Neuropalliative Clinical Trial

Glickman AJ¹, Macchi ZA², Sillau SH², Katz M³, Pantilat SZ⁴, Kluger BM^{5,6,7}

Departments of 1Psychiatry and 2Neurology, University of Colorado School of Medicine, Department of Neurology, University of California, San Francisco, CA, USA; 5Department of Neurology, University of California San Francisco, CA, USA; 5Department of Neurology, 6Center for Health + Technology

University of Rochester, and ⁷Department of Medicine, Palliative Care Division, Rochester, NY, USA;, University of Rochester, Rochester, NY, USA

Significance

- Care partner burden worsens mental and physical health, quality of life, overall disease management, and healthcare utilization for both care partners and people with Parkinson's disease and related disorders (PDRD)¹
- Cross-sectional studies show associations between care partner burden and psychological well-being, quality of life, and Parkinson's disease severity²
- Research gap: What risk factors worsen care partner burden over time?

Methods & Materials

- Design: Longitudinal observational study
- Recruitment: Data from care partner/patient dyads enrolled in a neuropalliative, multi-site, communitybased pragmatic trial
- Statistical analysis: Linear mixed regression models with outcome = 12month rate of change in self-reported burden, measured by the Zarit Burden Inventory (ZBI)

Results

Table 1. Baseline Patient & Care Partner Characteristics					
Characteristic	Patients		Care Partners		
Age, mean (SD)	74.5	(8.5)	67.6	(11.3)	
Gender, self-identified as male, No. (%)	200	(66.7)	71	(23.7)	
Race/Ethnicity, No. (%)					
African American	2	(0.7)	0	(0.0)	
Asian	7	(2.3)	8	(2.7)	
Native American	2	(0.7)	3	(1.0)	
Caucasian	286	(95.3)	282	(94.0)	
Other	3	(1.0)	3	(1.0)	
Hispanic/Latino, No. (%)	12	(4.0)	15	(5.0)	
Education, college degree, No. (%)	182	(61.7)	180	(60.8)	
Care partner relationship to patient, No. (%)					
Spouse/partner	_	_	231	(77.3)	
Son, daughter, or in-law	-	_	48	(16.1)	
Paid Caregiver	_	_	3	(1.0)	
Other	-	_	17	(5.7)	
Disease/caregiving duration, years, mean (SD)	9.0	(7.5)	5.0	(5.1)	
Patient's primary diagnosis, No. (%)					
Idiopathic Parkinson's disease	203	(67.7)	_	_	
Dementia with Lewy bodies	35	(7.0)	_	_	
Progressive supranuclear palsy	21	(4.0)	_	_	
Multiple systems atrophy	15	(5.0)	_	_	
Corticobasal degeneration, probable	12	(11.7)	_	_	
Dementia present, No. (%)	49	(16.3)	_	_	
Cognition, MOCA score, mean (SD)	21.2	(6.1)	_	_	
Disease severity, UPDRS-3 score, mean (SD)	26.7	(11.3)	_	_	
Anxiety, HADS-A score, mean (SD)	7.5	(3.9)	6.8	(3.9)	
Depression, HADS-D score, mean (SD)	7.8	(3.8)	4.6	(3.5)	
Quality of life, QOL-AD score, mean (SD)	35.1	(6.5)	_	_	
Care partner burden, ZBI, mean (SD)	_	_	16.5	(8.6)	
Abbreviations: M = mean; SD = standard deviation; MoCA = Montreal Cognitive Assessments Section; HADS = Hospital Anxiety and Depression Scale; QOL-AD = Quality of Life in Alzh Questionnaire 39; ZBI = Zarit Burden Interview.					

Table 2. Linear mixed regression models of baseline variables and ZBI scores at 6 & 12 months

	6 Months	12 Months	
Care Partner Characteristic	Beta (95% CI), t-value	Beta (95% CI), t-value	
Age (10 years)	-1.87 (-2.83, -0.90), -3.80***	-1.14 (-2.14, -0.14), -2.25*	
Perceptions of patient's QOL (QoL-AD CG; 5 units)	-3.31 (-4.10, -2.51), -8.18***	-2.46 (-3.31, -1.60), -5.67***	
Depression (HADS-D; 3 units)	2.82 (1.93, 3.72), 6.24***	2.29 (1.31, 3.26), 4.62***	
Anxiety (HADS-A; 3 units)	2.57 (1.76, 3.37), 6.28***	2.31 (1.44, 3.18), 5.24***	
Patient's health problems affecting CG iADLs (1 unit)	1.46 (1.03, 1.88), 6.73***	1.24 (0.76, 1.73), 5.07***	
Patient Characteristic	Beta (95% CI), t-value	Beta (95% CI), t-value	
MoCA score (5 units)	-1.4 (-2.88, 0.11), -1.82	-2.08 (-3.72, -0.44), -2.50*	
Fall in past 3 months (yes/no)	3.05 (0.79, 5.30), 2.66**	3.41 (1.06, 5.77), 2.86**	
Fall requiring medical treatment in past 3 months (yes/no)	3.60 (0.32, 6.88), 2.16*	5.43 (2.05, 8.82), 3.16**	

Discussion

- Consistent with established relationship between burden and psychological and physical health of care partners and patients
- Advances the science by establishing that these factors are intertwined not only at baseline, but also over time

Implications & Future Directions

Treating PDRD care partners' depression and anxiety may have additional benefits:

- Slow the increase in burden over time
- Ultimately improve PDRD disease severity Future directions:
- Clinical trials to test effects of interventions targeting care partners' depression and anxiety
- Developing integrated care models to screen and facilitate care for depression and anxiety in PDRD care partners

References

Edwards NE, Ruettiger KM. The influence of caregiver burden on patients' management of Parkinson's disease: implications for rehabilitation nursing. Rehabilitation nursing: the official journal of the Association of Rehabilitation Nurses 2002;27(5):182-186, 198.
Martinez-Martin P, Forjaz MJ, Frades-Payo B, et al. Caregiver burden in Parkinson's disease. Movement disorders: official journal of the Movement Disorder Society 2007;22(7):924-931; quiz 1060.